ARDA Software for the Detection of mtmDR

Recruiting in Palo Alto (17 mi)

+12 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Verily Life Sciences LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.

Eligibility Criteria

Inclusion Criteria

meet the criteria established by either the World Health Organization (WHO) or the American Diabetes Association (ADA)

Age 22 or older

Understand the study and volunteer to sign the informed consent

Treatment Details

Interventions

• ARDA software application (Software)

Participant Groups

Group I: Retinal Imaging and Mydriatic Agents Experimental Treatment 1 Intervention

Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Christie Clinic Champaign, IL

Riverside Diabetes Clinic Riverdale, MD

PMG Research of Winston Salem Winston-Salem, NC

Diabetes & Endocrinology Associates of Stark County, Inc Canton, OH

More Trial Locations

Who Is Running the Clinical Trial?

Verily Life Sciences LLC Lead Sponsor

Google LLC. Industry Sponsor

Optos, PLC Industry Sponsor

Nikon Corporation Collaborator

The Emmes Company, LLC Industry Sponsor

References